Hakkımda

Doç. Dr. Deniz Tural, M.D

Bakirköy Eğitim ve Araştırma Hastanesi/  Bakirköy-Istanbul

Tel: + 90 212 414 71 71 e-mail: deniztural@gmail.com

  • Eğitim
  •  Cerrahpaşa Tıp Fakültesi, İstanbul üniversitesi                                1996-2002

          –Tıp fakültesi öğrenci

 

  • Şişli  Eğitim ve Araştırma , İstanbul                                                 2003-2009

         –İç hasatlıkları  uzamanlık eğitimi

 

  • Cerrahpaşa Tıp Fakültesi, İstanbul üniversity                                 2010-2013

                     Medikal Onkoloji

          –Medikal onkoloji yandal eğitimi

 Meslek Deneyim

  • Akdeniz Üniversitesi Tıp Fakültesi, Antalya                                         2013-2014

                     Medikal Onkoloji

       -Medikal onkoloji

 

  • Bakirköy Eğitim ve Araştırma Hastanesi, İstanbul                      01. 2015-devam

Medical Onkoloji

                                      -Medikal Onkoloji

  

 

Araştırma ve Yayınlar

  1. Tural D, Batur S, Erdamar S, Akar E, Kepil N, Mandel NM, Serdengeçti S. Analysis of PTEN, BRAF and PI3K status for determinationof benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. Tumour Biol. 2014 ;35 :1041-9.
  2. Tural D, Yildiz O, Elcin O, Erdamar S, Guney S, Demireli F, Buyukunal E, Serdengecti S. What is the optimal treatment in clinical stage T3N0M0 rectal cancer?. J BUON. 2014; 19:97-102.
  3. Tural D, Selcukbiricik F, Özturk MA, Yildiz O, Turna H, Erdamar S, Büyükünal E, Serdengeçti S.The relation between pathological complete response and clinical outcome in patients with rectal cancer. Hepatogastroenterology. 2013 ;60:1365-70.
  4. Tural D, Selcukbiricik F, Erdamar S, Ozkurt CU, Yanmaz T, Mandel NM, Serdengeçti S. Association KRAS G13D tumor mutated outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab. Hepatogastroenterology. 2013 ;60:1035-40.
  5. Tural D, Serdengecti S, Demirelli F, Oztürk T, Ilvan S, Turna H, Ozgüroglu M, Büyükünal E. Clinical  significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Br J Cancer. 2014;110:1968-76.
  6. Tural D, Elicin O, Batur S, Arslan D, Oz B, Serdengecti S, Uzel O. Increase in the rate of HPV positive oropharyngeal cancers during 1996-2011 in a case study in Turkey. Asian Pac J Cancer Prev. 2013;14:6065-8.
  7. Tural D, Ozturk M, Selcukbiricik F, Yildiz O, Elicin O, Turna H, Guney S, Ozguroglu M. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer. J BUON.2013;18:385-90.
  8. Tural D, Selcukbiricik F, Yıldız O, Elcin O, Erdamar S, Güney S, Demireli F, Büyükünal E, Serdengeçti S. Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer.  Int J Clin Oncol. 2014; 19 :889-96.
  9. Selcukbiricik F, Tural D, Bilici A, Kocak Uzel E, Ozguroglu M, Demirelli F, Buyukunal E, Serdengeçti S. Clinicopathological Features and Localization of gastric cancers and their effects on survival in Turkey. Asian Pac J Cancer Prev. 2013;14:553-6.
  10. Selcukbiricik F, Buyukunal E, Tural D, Ozguroglu M, Demirelli F, Serdengecti S. Clinicopathological features and outcomes of patients with gastric cancer: a single-center experience. World J Gastroenterol. 2013;19:2154-61.
  11. Tural D, Selçukbiricik F, Akar E, Serdengeçti S, Büyükünal E. Gastric cancer: a case study in Turkey. J Cancer Res Ther. 2013;9:644-8
  12. Tural D, Eliçin O, Batur S, Arslan D, Öz B, Serdengeçti S, Uzel Ö. Human papillomavirus is independent prognostic factor on outcome of oropharyngeal squamous cell carcinoma. Tumour Biol. 2013;34:3363-9.
  13. Selcukbiricik F, Tural D, Erdamar S, Buyukunal E, Demirelli F, Serdengecti S. Is Helicobacter pylori a poor prognostic factor for HER-2 SISH positive gastric cancer? Asian Pac J Cancer Prev. 2013;14:3319-22.
  14. Selcukbiricik F, Tural D, Aydogan F, Bese N, Büyükünal E, Serdengeçti S. Male breast cancer: 37-year data study at a single experience center in Turkey. J Breast Cancer. 2013;16:60-5.
  15. Tural D, Selçukbiricik F, Serdengeçti S, Büyükünal E. A comparison of patient characteristics, prognosis, treatment modalities, and survival according to age group in gastric cancer patients. World J Surg Oncol.2012;10:234.
  16. Tural D, Selçukbiricik F, Aydogan F, Bese N, Yetmen O, Ilvan S, Büyükünal E, Serdengeçti S. Male breast cancers behave differently in elderly patients. Jpn J Clin Oncol. 2013 ;4:22-7.
  17. Selçukbiricik F, Tural D, Büyükünal E, Serdengeçti S. Perineural invasion independent prognostic factors in patients with gastric cancer undergoing curative resection. Asian Pac J Cancer Prev. 2012;13:3149-52.
  18. Selçukbiricik F, Tural D, Elicin O, Berk S, Ozgüroglu M, Bese N, Ferhanoglu B. Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease. ISRN Oncol. 2012;2012:951816.
  19. Tural D, Yildiz O, Selcukbiricik F, Ozturk MA, Keles Y, Oz B, Uzel O, Demir G, Mandel NM. Olfactory neuroblastomas: an experience of 24 years. ISRN Oncol. 2011;2011:451086.
  20. Arslan D, Tural D, Akar E. Herbal administration and interaction of cancer treatment. Journal of palliative medicine. J Palliat Med. 2013;16:1466-76.
  21. Tural D, Molinas Mandel N, Dervisoglu S, Oner Dincbas F, Koca S, Colpan Oksuz D, Kantarci F, Turna H, Selcukbiricik F, Hiz M. Extraskeletal Ewing’s sarcoma family of tumors in adults: prognostic factors and clinical outcome. Jpn J Clin Oncol. 2012;42:420-6.
  22. Tural D, Kilickap S. Is taxane-cisplatin-fluorouracil superior to cisplatin-fluorouracil as induction chemotherapy in outcome in locally advanced head and neck cancers?. J Clin Oncol. 2014;32:259.
  23. Arslan D, Tural D, Tatlı AM, Akar E, Uysal M, Erdogan G. Isolated uterine metastasis of invasive ductal carcinoma. Case Rep Oncol Med. 2013;2013:793418.
  24. Arslan D, Gündüz S, Tural D, Uysal M, Tatlı AM, Bassorgun CI, Elpek GÖ, Coskun HS, Bozcuk HS, Savas B. Inflammatory myofibroblastic tumor: a rarely seen submucosal lesion of the stomach. Case Rep Oncol Med.2013;2013:328108.
  25. Tural D, Selçukbiricik F, Günver F, Karısmaz A, Serdengecti S. Facial localization of malignant chondroid syringoma: a rare case report. Case reports in oncological medicine. 2013;2013:907980.
  26. Tural D, Selçukbiricik F, Erçalıskan A, Inanç B, Günver F, Büyükünal E. Metachronous rectum metastases from gastric adenocarcinoma: a case report. Case reports in medicine.2012;2012:726841.
  27. Tural D, Akar E, Oztürk T, Turna H, Serdengeçti S. Malignant clinical presentation of a benign granular cell tumor of breast in a patient with previously treated contralateral invasive ductal carcinoma. Case Rep Oncol Med.2012;2012:974740.
  28. Selcukbiricik F, Tural D, Senel TE, Sarıca A, Soyluk O, Serdengecti S. Bilateral Ischemic Optic Neuropathy Developed under Interferon Therapy. Case Rep Ophthalmol Med. 2012;2012:102739
  29. Selcukbiricik F, Tural D, Senel ET, Dervisoglu S, Serdengecti S. Gastric carcinoma with osteoblastic differentiation. Int J Surg Case Rep. 2012;3:516-9.
  30. Selcukbiricik F, Tural D, Ozturk MA, Dervisoglu S, Sager S, Hız M, Mandel NM.  Gastrointestinal stromal tumor of the rectum with scapular metastasis: a case report.  J Med Case Rep. 2012;6:145.
  31. Selcukbiricik F, Tural D, Bay A, Sahingoz G, Ilvan S, Mandel NM. A malignant mass in the breast is not always breast cancer. Case Rep Oncol. 2011;4:521-5.
  32. Papila B, Yildiz O, Tural D, Delil S, Hasiloglu ZI, Ayan F, Papila C. Wernicke’s Encephalopathy in Colon Cancer.  Case Rep Oncol. 2010;3:362-7.
  33. Selcukbiricik F, Tural D, Esatoglu N, Kocak S, Mandel NM. A very rare adult case with neuroblastoma. Case Rep Oncol. 2011;4:481-6.
  34. Selcukbiricik F, Bilici A, Tural D, Erdamar S, Soyluk O, Buyukunal E, Demirelli F, Serdengecti S. Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?. Tumour Biol. 2013;34:2233-9.
  35. Selcukbiricik F, Erdamar S, Ozkurt CU, Molinas Mandel N, Demirelli F, Ozguroglu M, Tural D, Buyukunal E, Serdengecti S.The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. J BUON.2013 ;18:116-23.
  36. Selcukbiricik F, Yalçın S, Tural D, Erdamar S, Demir G, Dogusoy G, Mandel NM. Gastrointestinal stromal tumors in Turkey: experiences from 3 centers. Onkologie. 2013;36:18-24
  37. Tural D, Selcukbiricik F, Sager S, Akar E, Yildiz O, Serdengecti SH.PET-CT changes the management and improves outcome in patients with recurrent colorectal cancer. J Cancer Res Ther. 2014;10:121-6.
  38. Arslan D, Bozcuk H, Gunduz S, Tural D, Tattli AM, Uysal M, Goksu SS, Bassorgun CI, Koral L, Coskun HS, Ozdogan M, Savas B. Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7th Edition Staging System. Asian Pac J Cancer Prev. 2014;15:2465-72
  39. Tural D, Yuce D, Kilickap S. Mortality in prostate cancer and use of statins.    J Clin Oncol. 2014;32:2274.
  40. Arslan D, Gündüz S, Avci F, Merdin A, Tatli AM, Uysal M, Tural D ,Başsorgun CI, Savaş B. Pilomatrix carcinoma of the scalp with pulmonary metastasis: A case report of a complete response to oral endoxan and etoposide. Oncol Lett. 2014;7:1959-1961.
  41. Tural D, Akar E, Mutlu H, Kilickap S. P95 HER2 fragments and breast cancer outcome. Expert Rev Anticancer Ther. 2014 ;14:1089-96.
  42. Arslan D, Merdin A, Tural D, Temizel M, Akın O, Gündüz S, Tatlı AM, Avcı F, Uysal M. The effect of autoimmunity on the development time of microvascular complications in patients with type 1 diabetes        mellitus. Med Sci Monit. 2014 ;20:1176-9.
  43. Mutlu H, Gündüz S, Büyükçelik A, Yıldız O, Uysal M, Tural D, Bozcuk H, Coşkun HS. The Necessity of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma Using Antiangiogenic Targeted Therapy After Interferon Alfa-2b. Clin Genitourin Cancer. 2014 Jun 8. pii: S1558-767300109-8.
  1. Yildiz I, Ekenel M, Akman T, Kocar M, Uysal M, Kanitez M, Varol U, Bayoglu IV,  Tural D, Kaplan MA, Avci N, Sürmeli Z, Dede I, Ulaş A, Yazici O, Basaran .Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial. Anticancer Res. 2014;34:4329-34.
  1. Kivrak Salim D, Mutlu H, Karakurt Eryilmaz M, Yalçin Musri F, Tural D, Coşkun HS. Metronomic maintenance chemotherapy in patients presenting with paraneoplastic autoimmune hepatitis with recurrent thymic carcinoma. J Oncol Pharm Pract. 2014 Sep 16. [Epub ahead of print]
  1. Eryilmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Coskun HS. The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Asian Pac J Cancer Prev. 2014;15(18):7737-40.
  1. Oksüz DC, Tural D, Dincbas FÖ, Dervisoglu S, Turna H, Hiz M, Kantarci F, Ceylaner B, Koca S, Mandel NM. Non-metastatic Ewing’s sarcoma family of tumors of bone in adolescents and adults: prognostic factors and clinical outcome-single institution results. Tumori. 2014; 100 :452-8.
  1. Tural D, Akar E, Öztürk MA, Yıldız Ö, Turna H, Serdengeçti S. Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma. J Cancer Res Ther. 2014 Jul-Sep;10(3):745-8. doi: 10.4103/0973-1482.136034
  1. Arslan D, Koca T, Akar E, Tural D, Ozdogan M. Cancer pain prevalence and its management. Asian Pac J Cancer Prev. 2014;15(20):8557-62.
  1. Salim DK, Mutlu H, Eryilmaz MK, Musri FY, Tural D, Gunduz S, Coskun HS. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors. Asian Pac J Cancer Prev. 2014;15(21):9379-83.
  1. Musri FY, Mutlu H, Kıvrak Salim D, Karakurt Eryılmaz M, Ünal B, Tural D, Şenol Coşkun H. Sorafenib-induced severe urticaria in a patient with hepatocellular cancer. J Oncol Pharm Pract. 2015 Jan 6. pii: 1078155214565126. [Epub ahead of print]

Yurt içi ve Yurt dışı kongrelerde  sunulmuş çok sayıda bildiri.

Sertifikaları: European Society for Medical Oncology(ESMO Examination Certificate),  Tıbbi Onkoloji Yeterlilik Belgesi

  

Üye Olduğu dernekler:

 

  • American Society of Clinical Oncology
  • European Society For Medical Oncology
  • Turkish Society of Clinical Oncology
  • Türk Tabibler Birliği